Memantine Hydrochloride Tablet, Film Coated
Product Images NDC 55154-4151

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 55154-4151). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

2815463f 49a5 4573 A623 Ccce40d5f459 00

Label for Memantine Hydrochloride Tablets USP 10 mg, package containing 10 tablets. The label includes storage instructions, usage warnings, and distribution information. Manufactured by Dr. Reddy's Laboratories Limited, India, and distributed by Major Pharmaceuticals and Cardinal Health in the USA.*

FDA Label Image

2815463f 49a5 4573 A623 Ccce40d5f459 01

Memantine Hydrochloride Tablets, USP 5 mg film-coated tablets, package of 10 tablets. The label includes the NDC code 55154-4151-0 and identifies the product as prescription-only. Manufacturer is Dr. Reddy's Laboratories Limited, India, with distribution by MAJOR Pharmaceuticals and Cardinal Health. The label includes storage instructions and warnings about child resistance and institutional use.*

FDA Label Image

Figure1

A line graph showing the mean change from baseline in ADCS-ADL scores over weeks of treatment, comparing placebo and Memantine Hydrochloride (Memantine HCl). The graph illustrates clinical improvement and decline with data points at 4, 12, and 28 weeks, including error bars for standard error.*

FDA Label Image

Figure2

A cumulative percentage graph comparing the effect of Memantine Hydrochloride versus placebo on ADCS-ADL change from baseline. The x-axis represents the change from baseline in ADCS-ADL scores, while the y-axis shows the cumulative percentage of patients. Two lines are depicted, one for placebo and one for Memantine HCl, illustrating their distribution across the measured outcome.*

FDA Label Image

Figure3

A line graph showing mean change in SIB (Severe Impairment Battery) score from baseline over 28 weeks of treatment. It compares two groups: Placebo and Memantine Hydrochloride (Memantine HCl). The graph indicates trends toward clinical improvement or decline, with error bars representing SEM (standard error of the mean).*

FDA Label Image

Figure4

A cumulative percentage plot showing patients' SIB change from baseline comparing Memantine Hydrochloride and placebo groups. The x-axis represents SIB change from baseline and the y-axis shows the cumulative percentage of patients. The graph uses different markers to distinguish Memantine HCl from placebo.*

FDA Label Image

Figure5

A line graph depicting the mean change in ADCS-ADL scores from baseline over 24 weeks of treatment. Two groups are shown: Placebo/Donepezil and Memantine HCl/Donepezil. The x-axis represents weeks of treatment from 0 to 24, and the y-axis represents mean change scores indicating levels of clinical improvement or decline.*

FDA Label Image

Figure6

A line graph comparing the cumulative percentage of patients showing ADCS-ADL change from baseline between two groups: placebo/donepezil and Memantine HCl/donepezil. The x-axis represents the ADCS-ADL change from baseline, while the y-axis shows the cumulative percentage of patients.*

FDA Label Image

Figure7

A line graph depicting the mean change from baseline in ADCS-ADL score over 24 weeks of treatment comparing Memantine HCl/Donepezil to Placebo/Donepezil. The y-axis shows the mean change, the x-axis shows weeks of treatment, with Memantine HCl/Donepezil showing greater clinical improvement over time compared to placebo.*

FDA Label Image

Figure8

A line chart comparing cumulative percentage of patients versus SIB change from baseline, showing data for Memantine HCl/Donepezil and Placebo/Donepezil groups. The graph depicts patient response distributions over a range of SIB score changes.*

FDA Label Image

Structure

Chemical structure of Memantine Hydrochloride showing a tricyclic amine with two methyl groups and an amine group attached, along with the hydrochloride salt.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.